

17TH INTERNATIONAL CONFERENCE OF THE
RESEARCH INSTITUTE OF OPHTHALMOLOGY

RIO 2025

*Anterior Segment Eye Diseases
Current Status & Future Directions*



Photobiomodulation

***Dr. M. Mohamed-Aly
Ibrahim***

MD, FRCS,

***Ass. prof of ophthalmology
Al Azhar University - Cairo***



WHAT IS Photobiomodulation?

- ✓ It is conversion of light energy to metabolic energy, with a corresponding change of cell's biological functions
- ✓ Also known as **low-level laser therapy**, and far-red to near-infrared (**FR/NIR**) light therapy.
- ✓ It consists of series of brief illumination with FR/NIR light (600-1000 nm) from a laser or a light emitting diode (LED).

History

- ✓ At the end of the 18th century Finsen (the "father of phototherapy") had cured skin disorders such as
 - Small blisters using red light
 - lupus vulgaris using UV light.
- ✓ He won the 1903 Nobel Prize in Medicine and Physiology "in recognition of his contribution to the treatment of these diseases.
- ✓ Medical usefulness of FR/NIR light had been "re-discovered" for a second time upon the invention of the laser in the 1960s.

History 2

- ✓ It happened due to unexpected research outcome where **Mester** attempted to use laser-derived 694 nm light to induce skin cancer in mice.
- He shaved the mouse fur covering the location where the light would be applied.
- Light caused the fur to re-grow faster in treated mice compared with untreated control (instead of inducing cancer).

Clinical applications

- ✓ Over the years, PBM was used in several conditions, with the majority having been explored in both animal models and human patients with a spectrum of:
- ✓ Wound healing: including diabetic ulcers.
- ✓ Pain control: for neurologic neck pain, and pain from chronic joint disorders.
- ✓ Promotion of the regeneration and functional recovery of tissues with poor healing potential such as:
 - injured peripheral and optical nerves.
 - recovery following stroke and other central nervous system damage such as traumatic brain injury.

Clinical application

- ✓ PBM offers non-invasive therapeutic approach to challenging sight-threatening retinal conditions.
- ✓ **Potential targets include:**
 - Age-related macular degeneration (AMD),
 - Retinopathy of prematurity (ROP),
 - Diabetic retinopathy (DR)
 - Leber's hereditary optic neuropathy
 - Methanol-induced retinal damage
 - Amblyopia.
 - Glaucoma and possibly others.

Mechanism of action

- ✓ Different wavelengths of light have different degrees of *absorption, scattering, and reflection* by biological media and tissues.
- ✓ Generally, biological tissues contain a range of chromophores such as:
 - Water molecules (significantly absorb light energy at wavelengths greater than 970 nm)
 - Oxyhemoglobin (HbO₂), deoxyhemoglobin (Hb), myoglobin, melanin, and flavins. (absorb wavelengths shorter than 600 nm).
- ✓ For these reasons, there is an **optical window for PBM therapy** in the range of the red to NIR spectrum
 - Cytochrome c oxidase in mitochondria
 - Light gated ion channels and opsins

Mechanism of action 2

- ✓ In conventional laser medicine heating and burning are the prevailing mechanisms of action.
- ✓ PBM uses the photochemical conversion potential of low-intensity FR/NIR (630-1000 nm) light
- ✓ Studies in the late 1980s and 1990s that implicated mitochondria as the subcellular targets of FR/NIR. It was proposed by **Karu** that cytochrome C oxidase inside

Cytochrome c oxidase in mitochondria

✓ **Cytochrome C oxidase** is the enzyme that catalyzes the transfer of electrons from cytochrome C to molecular oxygen-the final step in the mitochondrial respiratory chain and essential for the sustained availability of energy inside cells.

✓ **Nitric oxide (NO):**

- Increasing the bioavailability of **nitric oxide** (vasodilator) by prompting its release from intracellular stores such as heme-containing proteins.

Cytochrome c oxidase in mitochondria

- ✓ 670 nm light completely reverses the ability of tetrodotoxin, (a sodium channel blocker capable of indirect down-regulation of cytochrome C oxidase)
- ✓ PBM competed with potassium cyanide (an irreversible inhibitor of cytochrome C oxidase)
- ✓ NIR light reverses the inhibitory and toxic effect of formic acid (the active metabolite in methanol intoxication), on mitochondrial cytochrome C oxidase in rat retinas, resulting in improved vision outcomes

Continue (neuroprotection)..

✓ Direct effect of PBM on the gene expression and metabolism of photoreceptor cells:

- Upregulation in the proteins that involve the mitochondrial respiratory chain and anti-oxidant genes
- Downregulation of genes implicated in apoptosis and the stress response.

✓ PBM effect on susceptible stem cells, progenitor cells:

- It has a potential in enhancing differentiation, which in turn improves the healing rate of tissues.

Mechanism of action Sum (PBM).


Mitochondrial activation:

increase ATP
(energy), reduces oxidative

stress
Improves blood flow
(vasodilation)
Neuroprotective effect

(stimulates neurogenesis &
protect cells from

apoptosis
Anti inflammatory effect



Role of Photobiomodulation in the Retina-AMD

- ✓ Cones in the aging human retina (mostly at the fovea), progressively accumulate mitochondrial DNA deletions and become more cytochrome C oxidase-deficient over time
- ✓ It is well known that inflammation, complement activation, is associated with the pathogenesis of AMD
- ✓ Since both mitochondria's health and the inflammatory state are influenced by PBM, it obvious that FR/NIR light could treat AMD
- ✓ Evidence for the application of PBM to treat AMD in humans became available in 2008 from a study where Ivandic and Ivandic demonstrated improvement in visual acuity (VA) in patients with the dry and wet forms of AMD.

(Ivandic BT, Ivandic T. Low-level laser therapy improves vision in patients with age-related macular degeneration. *Photomed Laser Surg.* 2008;26(3):241-245.)

Diabetic retinopathy

- ✓ laser photocoagulation, performed with conventional continuous wave (cw) laser systems cause damage to the neural retinal microstructures by **thermal spread from the RPE**.
- ✓ PBM **reverse the diabetes-induced inflammatory state** of the retina by reduction in leukostasis (the adherence of white blood cells to the retinal vascular walls) and in the expression of the intercellular adhesion molecule (ICAM).
- ✓ PBM also led to **inhibition of the diabetes-induced production of the oxidative-stress molecule superoxide** and reversed the decrease in the anti-oxidant enzyme.

Retinopathy of prematurity

- ✓ The mechanism involves the generation of reactive oxygen species which lead to inflammation and oxidative damage to DNA, including mitochondrial DNA, as well as damage to intracellular proteins and lipids
- ✓ Pre-treatment with 670 nm light reduces neovascularization, vaso-oblitration, retinal hemorrhages, and photoreceptor cell death.

Methanol toxicity in the retina

- ✓ The toxic metabolite in methanol intoxication is **formic acid**, (a mitochondrial toxin known to inhibit the essential mitochondrial enzyme, cytochrome oxidase) leading to decline of mitochondrial function.
- ✓ treatment with 670 nm light for 2.5min at 5, 25, and 50h after methanol poisoning was able to rescue retinal function in a rat

Therapeutic photobiomodulation for methanol-induced retinal toxicity

J. T. Eells^{*†}, M. M. Henry^{*}, P. Summerfelt[‡], M. T. T. Wong-Riley[‡], E. V. Buchmann[§], M. Kane[§], N. T. Whelan[§], and H. T. Whelan[§]

Retinitis pigmentosa

- ✓ The evidence for this is currently scarce and consists of a single case report.
- ✓ Treatment with transconjunctival illumination of the whole retina with 780 nm light, generated by a continuous-wave laser diode, for 40s for a total of 0.4 J/cm² per 2wk

Ivandic BT, Ivandic T. Low-level laser therapy improves vision in a patient with retinitis pigmentosa. *Photomed Laser Surg.* 2014;32(3):181–184. Ivandic BT, Ivandic T. Low-level laser therapy improves vision in a patient with retinitis pigmentosa. *Photomed Laser Surg.* 2014;32(3):181–184.

Reported to improve vision.

Amblyopia in adolescents and adults

- ✓ Amblyopia becomes untreatable after the "critical period" (after the first-decade of life).
- ✓ Evidence that amblyopia in older patients could benefit from PBM was demonstrated by Ivandic and Ivandic
- ✓ No therapy-related ocular or systemic side effects reported.
- ✓ Authors speculated that the mechanism through which PBM improves amblyopic eyes, might be similar to those in other retinal conditions

Ivandic BT, Ivandic T. Low-level laser therapy improves visual acuity in adolescent and adult patients with amblyopia. Photomed Laser Surg. 2012;30(3):167

Slowing axial myopia in children



Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children

A Multicenter Randomized Controlled Trial

Yu Jiang, MD,^{1,2,*} Zhuoting Zhu, MD, PhD,^{2,3,*} Xingping Tan, MD,^{2,3,*} Xiangbin Kong, MD, PhD,^{4,5,*} Hui Zhong, PhD,^{6,*} Jian Zhang, MD,⁷ Ruilin Xiong, MD,⁷ Yixiong Yuan, MD,⁷ Junwen Zeng, MD, PhD,⁷ Ian G. Morgan, PhD,² Mingguang He, MD, PhD^{2,3,7}

Purpose: To assess the efficacy and safety of repeated low-level red-light (RLRL) therapy in myopia control in children.

Design: Multicenter, randomized, parallel-group, single-blind clinical trial.

Participants: Two hundred sixty-four eligible children 8 to 13 years of age with myopia of cycloplegic spherical equivalent refraction (SER) of -1.00 to -5.00 diopters (D), astigmatism of 2.50 D or less, anisometropia of 1.50 D or less, and best-corrected visual acuity (BCVA) of 0.0 logarithm of the minimum angle of resolution or more were enrolled in July and August 2019. Follow-up was completed in September 2020.

Methods: Children were assigned randomly to the intervention group (RLRL treatment plus single-vision spectacle [SVS]) and the control group (SVS). The RLRL treatment was provided by a desktop light therapy device that emits red light of 660 nm wavelength at an illuminance level of approximately 1600 lux and a power of



Axial Shortening in Myopic Children after Repeated Low-Level Red-Light Therapy: Post Hoc Analysis of a Randomized Trial

Wei Wang *¹, Yu Jiang *¹, Zhuoting Zhu *^{1,2}, Shiran Zhang *¹, Meng Xuan¹, Xingping Tan³, Xiangbin Kong⁴, Hui Zhong⁵, Gabriella Bulloch^{2,6}, Ruilin Xiong⁷, Yixiong Yuan⁷, Yanping Chen¹, Jian Zhang⁷, Junwen Zeng⁷, Ian G Morgan², Mingguang He^{2,9,10}

Affiliations: [+ expand](#)

PMID: 36790672 PMCID: PMC10011250 DOI: 10.1007/s40123-023-00671-7

Abstract

Introduction: Axial length (AL) elongation in myopia is considered irreversible. We aimed to systemically report unexpected AL shortening observed in a randomized clinical trial (RCT) after repeated low-level red-light (RLRL) therapy.

Methods: This is a post hoc analysis of a multicenter, single-masked RCT. Two hundred sixty-four

- ✓ Home based device
- ✓ Tx for 3 minutes, 2 times daily
- ✓ 5 days / week
- ✓ Minimum of 4 hours

Meibomian gland dysfunction

ORIGINAL ARTICLE

Treatment of dry eye disease due to meibomian gland dysfunction using intense pulsed light and low-level light therapy

Khalifa, Ali A.; Ibrahim, Mohamed M.A.; Abdelrahman, Mahmoud S.A.

Author Information 

Delta Journal of Ophthalmology 22(2):p 91-96, Apr-Jun 2021. | DOI: 10.4103/djo.djo_68_20



- ✓ Many of the previous studies were done on animal models
- ✓ Through closed eye lids
- ✓ Whole body or whole retinal illumination
- ✓ Some requires overnight stay at hospitals or home therapy

What is new??

- ✓ Now we can benefit from PBM utilizing micropulse diode laser as a **SOURCE OF LIGHT**
- ✓ Can be done using slit-lamp delivery system
- ✓ Through the pupil



Why micropulse ??

Reduced risk of thermal damage

Enhanced cellular response

Potential for deeper tissue penetration

Less painful with minimal side effects


Utilizing PBM
principles-MPL
team Al-Azhar
UN hosp.




Chronic CSR-MPL team Al-Azhar UN *hosp.*



- ✓ 6m not responding to medical tx
- ✓ Transpupillary MPL
- ✓ Treatment of healthy peripheral retina.





Chronic CSR -MPL team Al-Azhar UN hosp.




CNV-MPL team Al-Azhar UN hosp.


- ✓ CNV comp. best disease
- ✓ Treatment of the macula & healthy peripheral retina.



Vien occlusion , trans-scleral MPL



Vien occlusion , trans-scleral MPL





OA Glaucoma-PBM.

- ✓ Transconjunctival peripheral-retinal Diode 810 nm (800 - 900 mw, 10% DC, 0.2 exp. time & 400 SZ)
- ✓ 1 session / wk for 1m then once monthly for 6 months
- ✓ IOP reduction probably due to increased uveo-scleral outflow
- ✓ There were also improvements in BCVA & VF .. This needs further F/U studies.
- ✓ Though VF was repeated many times before and after tx, patient learning curve should be considered.





OA Glaucoma-PBM.

- ✓ Lt eye F.pt .
- ✓ 63 yrs
- ✓ C/D 0.6
- ✓ On
BB/ acetazolamide
& alpha agonist ED
- ✓ BCVA improved
from 6/ 24 to 6/ 12
- ✓ IOP decreased
from 20 to 12
mmhg



OA Glaucoma-PBM.

- ✓ Rt eye F.pt .
- ✓ 62yrs
- ✓ C/D 0.7
- ✓ On
BB/ acetazolamide
ED
- ✓ BCVA improved
from 6/ 24 to
6/ 18
- ✓ I OP decreased
from 19 to 14
mmhg



Mechanism of PBM in Glaucoma.

Reduces inflammation

Improves blood flow (ON, Uveo-scleral outflow ..)

Neuroprotective effect (stimulates neurogenesis & protect RGC from apoptosis)

Studies showed reduced IOP, improved visual function & neuroprotective effect

Advantages of PBM

Non-invasive : minimal
risk of infection



Minimal side effects



Wide range of applications



Complementary to other
therapies

Disadvantages of PBM

Limited research needed to optimize parameters



Inconsistent results



Cost : PBM devices can be expensive



Take home message

- PBM involves conversion of light energy to metabolic energy → improving cell respiration & energy production.
- It consists of series of brief illumination with FR/ NIR light (600-1000 nm) from a laser or a light emitting diode (LED).
- It has many systemic & ocular applications
- It's safer, less destructive & less invasive than other treatments (argon laser, I.V.I...etc)
- PBM can be useful in Promotion of the regeneration and functional recovery of tissues with poor healing potential like neurological tissues (can be considered in regenerative medicine)

Thank You!